» Articles » PMID: 33417247

Multidrug Resistance-associated Protein 4 (Mrp4) is a Novel Genetic Factor in the Pathogenesis of Obesity and Diabetes

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2021 Jan 8
PMID 33417247
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Multidrug resistance protein 4 (Mrp4) is an efflux transporter known to transport several xenobiotics and endogenous molecules. We recently identified that the lack of Mrp4 increases adipose tissue and body weights in mice. However, the role of Mrp4 in adipose tissue physiology are unknown. The current study aimed at characterizing these specific roles of Mrp4 using wild-type (WT) and knockout (Mrp4 ) mice. Our studies determined that Mrp4 is expressed in mouse adipose tissue and that the lack of Mrp4 expression is associated with adipocyte hypertrophy. Furthermore, the lack of Mrp4 increased blood glucose and leptin levels, and impaired glucose tolerance. Additionally, in 3T3-L1 cells and human pre-adipocytes, pharmacological inhibition of Mrp4 increased adipogenesis and altered expression of adipogenic genes. Lack of Mrp4 activity in both of our in vivo and in vitro models leads to increased activation of adipose tissue cAMP response element-binding protein (Creb) and decreased plasma prostaglandin E (PGE) metabolite levels. These changes in Creb activation, coupled with decreased PGE levels, together promoted the observed metabolic phenotype in Mrp4 mice. In conclusion, our results indicate that Mrp4 as a novel genetic factor involved in the pathogenesis of metabolic diseases, such as obesity and diabetes.

Citing Articles

Investigating the crosstalk between and in 3T3-L1 adipocyte differentiation.

Laddha A, Wahane A, Bahal R, Manautou J Front Mol Biosci. 2024; 11:1498946.

PMID: 39717760 PMC: 11663720. DOI: 10.3389/fmolb.2024.1498946.


Obesity-related drug transporter expression alterations in human liver and kidneys.

Kosicka-Noworzyn K, Romaniuk-Drapala A, Sheng Y, Yohn C, Brunetti L, Kagan L Pharmacol Rep. 2024; 76(6):1429-1442.

PMID: 39412582 PMC: 11582170. DOI: 10.1007/s43440-024-00665-7.


Progress and challenges of multidrug resistance proteins in diseases.

Ding P, Gao Y, Wang J, Xiang H, Zhang C, Wang L Am J Cancer Res. 2022; 12(10):4483-4501.

PMID: 36381332 PMC: 9641395.


Bioinformatics prediction and experimental verification of key biomarkers for diabetic kidney disease based on transcriptome sequencing in mice.

Zhao J, He K, Du H, Wei G, Wen Y, Wang J PeerJ. 2022; 10:e13932.

PMID: 36157062 PMC: 9504448. DOI: 10.7717/peerj.13932.


The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.

Walker O, Dahn M, Power Coombs M, Marcato P Front Oncol. 2022; 11:791696.

PMID: 35127497 PMC: 8807694. DOI: 10.3389/fonc.2021.791696.

References
1.
Zhang J, Klemm D, Vinson C, Lane M . Role of CREB in transcriptional regulation of CCAAT/enhancer-binding protein beta gene during adipogenesis. J Biol Chem. 2003; 279(6):4471-8. DOI: 10.1074/jbc.M311327200. View

2.
Cyranka M, Veprik A, McKay E, van Loon N, Thijsse A, Cotter L . Abcc5 Knockout Mice Have Lower Fat Mass and Increased Levels of Circulating GLP-1. Obesity (Silver Spring). 2019; 27(8):1292-1304. PMC: 6658130. DOI: 10.1002/oby.22521. View

3.
Cheepala S, Pitre A, Fukuda Y, Takenaka K, Zhang Y, Wang Y . The ABCC4 membrane transporter modulates platelet aggregation. Blood. 2015; 126(20):2307-19. PMC: 4643005. DOI: 10.1182/blood-2014-08-595942. View

4.
Xu H, Fu J, Miao Y, Wang C, Han Q, Li S . Prostaglandin E2 receptor EP3 regulates both adipogenesis and lipolysis in mouse white adipose tissue. J Mol Cell Biol. 2016; 8(6):518-529. PMC: 5181317. DOI: 10.1093/jmcb/mjw035. View

5.
More V, Slitt A . Alteration of hepatic but not renal transporter expression in diet-induced obese mice. Drug Metab Dispos. 2011; 39(6):992-9. PMC: 3100907. DOI: 10.1124/dmd.110.037507. View